Medtech sector set for growth as Poolbeg Pharma leads AI-driven innovation

The medtech industry is at a crucial point, experiencing significant growth driven by the Covid-19 pandemic, which spurred a wave of innovation and investment. Though the sector has now returned to pre-pandemic growth trends, this transition offers a rare chance for the industry to redefine itself. The rising demand for personalised healthcare, combined with advancements in digital technology, is paving the way for a more connected and patient-focused healthcare environment.

Despite the challenges posed by geopolitical issues, regulatory changes, and economic pressures, the industry is set to benefit from rapidly evolving technologies. Innovations such as artificial intelligence, machine learning, robotics, 5G, AR/VR systems, and IoT are reshaping the healthcare landscape. These advances are not just small improvements but are transforming how healthcare is delivered, with the medtech sector undergoing an innovation boom that rivals any other tech-driven field in terms of growth potential and impact.

The industry stands at a point where its value is set to increase, with opportunities for life-improving breakthroughs and long-term growth. With seamless data sharing, virtual care, and advanced AI-driven diagnostics on the horizon, the healthcare system is poised to become more efficient and effective. This shift will not only improve patient outcomes but also create new opportunities for medtech companies. Smaller firms, in particular, are well-positioned to lead this change, given their agility and willingness to embrace bold innovations.

A notable example in this evolving landscape is Poolbeg Pharma, a biopharmaceutical company with a market cap of £56m. Poolbeg focuses on developing treatments for critical unmet medical needs, such as cancer immunotherapy-induced CRS, infectious diseases, and metabolic conditions like obesity and diabetes. The company is a leader in AI-accelerated drug development, partnering with firms like CytoReason and OneThree Biotech to tackle infectious diseases such as influenza and RSV.

Poolbeg’s AI programmes, which use data from decades of human trials, have identified promising drug targets in significantly shorter timeframes than traditional methods. Both its influenza and RSV programmes are currently in preclinical stages, with strong near-term potential. The rapid progress in AI-driven drug discovery has attracted major pharmaceutical companies, some of which are in discussions with Poolbeg, as the process reduces costs, lowers risks, and increases the likelihood of success.

The company’s flagship product, POLB 001, is a Phase 2-ready anti-inflammatory candidate aimed at preventing CRS, a common side effect of cancer immunotherapies. POLB 001 has the potential to expand the use of these therapies to outpatient settings, opening up a $10bn market opportunity. As cancer immunotherapies grow, expected to reach $100bn by 2030, POLB 001 is positioned as a key player.

Recently, Poolbeg strengthened its leadership by bringing in a team from Amryt Pharma, which was sold for €1.48bn, with Cathal Friel, the founder of Amryt and other firms like hVIVO, joining as Executive Chairman. Poolbeg ended FY23 with a strong cash balance of £12.2m, ensuring continued growth and expansion in the coming year.

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model. 

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
X
LinkedIn

More articles like this

Poolbeg Pharma’s Oral GLP-1R agonist for metabolic disease

Poolbeg Pharma has developed a delivery system designed to enhance oral administration of GLP-1R agonists. This scalable, GRAS (Generally Recognised as Safe)-approved technology allows metabolic peptides to reach specific gut regions and enter systemic circulation, targeting

Poolbeg Pharma Scientist discusses Oral GLP-1 receptors

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model. 

POLB 001: A promising treatment for severe influenza

Severe influenza is marked by an excessive immune response, which can cause considerable damage to the lungs and affect other organs. This uncontrolled reaction often leads to hospitalisation due to the impact it has on the

Advancements shaping the future of drug discovery

The landscape of drug discovery has long been known for its complexity and the substantial time and financial resources required to bring a single drug to the market. Traditional methods, while forming the backbone of the

Poolbeg Pharma patent portfolio significantly strengthened & expanded

Poolbeg Pharma plc (LON: POLB), a clinical-stage biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, has announced its unaudited interim results for the six months to 30 June 2024.

UCD leads in research collaboration and Poolbeg Pharma partnership

University College Dublin (UCD) has been recognised for leading the way in research collaboration with industry in Ireland, according to Knowledge Transfer Ireland’s latest Annual Knowledge Transfer Survey (AKTS) for 2023. UCD, through its knowledge transfer

Cathal Friel on resilience, ambition and Ireland’s future

Business & Finance, established in 1964, is celebrating its 60th anniversary this year. To mark this milestone, the publication is conducting a series of Leadership interviews with influential figures shaping Ireland’s corporate landscape. One of these

AI’s impact on infectious disease drug development

Artificial intelligence (AI) represents a sophisticated form of machine learning capable of swiftly analysing extensive datasets, uncovering non-obvious patterns, and pinpointing novel disease targets along with potential drugs. AI is increasingly influencing drug development by identifying

Poolbeg Pharma’s innovative POLB001 demonstrates promising potential

Poolbeg Pharma plc, a forward-thinking biopharmaceutical company, has recently garnered attention for its groundbreaking work with POLB001, a novel therapeutic candidate showing significant promise in clinical research. As an emerging player in the pharmaceutical industry, Poolbeg

John McEvoy: The journey of an Irish unicorn

A unicorn is the title given to a start-up company that achieves a billion-dollar valuation. Newry-based John McEvoy was previously the Global General Counsel at a Dublin-based pharmaceutical company—a job he landed before he was 30—where

AI revolutionises drug discovery and pharmaceutical research

The future of drug discovery and pharmaceutical research is being reshaped by artificial intelligence (AI), heralding a new era of speed, efficiency, and precision. AI’s potential to accelerate drug development, from molecular prediction to optimised design